Pharmesis International Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company's revenue was RMB 18,332,000 against RMB 17,275,000 a year ago, mainly due to higher revenue from both the Group's prescribed drugs segment and non-prescribed drugs/distribution segment. Profit from operations was RMB 69,000 against loss of RMB 74,000 a year ago. Loss before tax was RMB 120,000 against RMB 255,000 a year ago. Loss attributable to the owners of the company was RMB 406,000 or 1.8 cents per fully diluted share against RMB 454,000 or 2.0 cents per fully diluted share a year ago. Net cash flows used operating activities were RMB 4,718,000 against net cash flows from operating activities of RMB 1,747,000 a year ago, mainly due to cash generated from its operations and changes in working capital. Acquisition of property, plant and equipment was RMB 624,000 against RMB 120,000 a year ago. For the six months, revenue was RMB 33,696,000 against RMB 31,588,000 a year ago. Profit from operations was RMB 405,000 against loss of RMB 982,000 a year ago. Profit before tax was RMB 59,000 against loss of RMB 1,314,000 a year ago. Loss attributable to the owners of the company was RMB 883,000 or 3.8 cents per fully diluted share against RMB 1,550,000 or 6.7 cents per fully diluted share a year ago. Net cash used in operating activities was RMB 256,000 against RMB 117,000 a year ago. Acquisition of property, plant and equipment was RMB 971,000 against RMB 329,000 a year ago.